Quarterly Activity Report — Quarter Ending 30 September 2021
Q3 highlights: Sites added for MagSense® HER2 Breast Cancer Phase I Study Experienced Chief Development Officer added to Management Team Joint Development…
Q&A with Chief Development Officer Yalia Jayalakshmi, Ph.D.
In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company's mission, and the…
Supplementary Announcement IBX / Global Cancer Technology
Further to the announcement made on 13th August 2021, Imagion Biosystems Limited provides this supplementary announcement in relation to the agreement with…
Imagion Biosystems September 2021 Investor Newsletter
Imagion Biosystems is pleased to provide its investors with its September 2021 Investor Newsletter. The newsletter details recent new company developments…
Imagion Biosystems Half-Year Results for the First Half of 2021 and Appendix 4D
1H2021 Highlights: Enrolment for the Phase I HER2 Breast Cancer Study commences Initiation of research for prostate cancer imaging supported by CSIRO funds…
Imagion Biosystems Enters Agreement to Develop Nanocrystals for Treating Breast Cancer
Imagion Biosystems is pleased to announce it has entered into a Joint Development Agreement with Global Cancer Technology (GCT), to develop GCT’s novel…
Quarterly Activity Report and Appendix 4C for 30 June 2021
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2021. The report highlights that during the quarter the…
Imagion Biosystems Receives A$2.6 Million R&D Tax Incentive
Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation…
Annual General Meeting Presentation Visuals
The presentation visuals from the Annual General Meeting of Imagion Biosystems are now available. Please click to view the presentation visuals at ASX.
Presentation Visuals from 28th May 2021 Annual General Meeting
The presentation visuals from the 28th May 2021 Annual General Meeting are now available. Download here.